Tevard Biosciences Presents Preclinical Data Showing Complete Dystrophin Restoration and Robust Titin Rescue with Suppressor tRNA Therapy at ASGCT 2026

Tevard Biosciences, Inc., a biotechnology company focused on tRNA-based therapies for genetic diseases, presented new preclinical data at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, held from May 11-15 in Boston. The data highlight the company's next-generation suppressor tRNAs (sup-tRNAs) that restore full‑length dystrophin protein and achieve wild-type levels of functional rescue in multiple mouse models of nonsense mutation-mediated Duchenne muscular dystrophy (DMD). Additionally, Tevard presented data showing durable rescue of full-length titin protein in a mouse model and functional rescue in human cardiomyocyte models of dilated cardiomyopathy caused by TTN truncations (DCM‑TTNtv).

According to the announcement, Tevard's next‑generation suppressor tRNAs achieve approximately 100% restoration of full‑length dystrophin in DMD models and deliver durable full‑length titin rescue in TTN‑related cardiomyopathy. The company's compact tRNA architecture enables flexible AAV packaging, precise dose control, and broad applicability for pathogenic nonsense mutations across diverse unmet medical needs. The presented programs underscore the versatility of the suppressor tRNA platform and its ability to restore native protein expression in a cell-specific, durable manner.

For more details, including downloadable images and bios, viewers can access the full announcement at www.tevard.com. Tevard Biosciences is advancing programs in muscular dystrophies, heart disease, and neurological disorders, aiming to cure a broad range of genetic diseases by restoring endogenous, full‑length protein expression for diseases caused by premature termination codons.